Johnson & Johnson leans on two main drugs for almost all Q2 sales growth
NEW BRUNSWICK, New Jersey, July 15, 2026, 10:08 (EDT) Tremfya and Darzalex made up $1.528 billion of Johnson & Johnson’s $1.567 billion jump in reported sales. Tremfya made up 94% of Stelara’s…
Read the full articleYou might also wanna read
Eli Lilly (NYSE:LLY) Shares Rise After Atai Partnership Could Unlock $1 Billion in Milestones
ts2.tech·13h ago
Health stocks today: Abbott (NYSE: ABT) jumps 11% as insurers split
ts2.tech·15h ago
AtaiBeckley (NASDAQ: ATAI) stock jumps on Lilly deal as market discounts milestones
ts2.tech·20h ago
Pfizer (NYSE:PFE) Faces New Patent Claim After $96 Billion in COVID Vaccine Revenue
ts2.tech·1d ago
Pfizer (NYSE:PFE) scores FDA approval but Wall Street reaction muted
ts2.tech·4d ago
HSBC Upgrades Apple to Buy From Hold, Raises Price Target to $366
en.bloomingbit.io·1h ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.